Tandem Diabetes Care Stock Forecast, Price & News

Tandem Diabetes Care's stock was trading at $66.33 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, TNDM shares have increased by 64.3% and is now trading at $109.00.
View which stocks have been most impacted by COVID-19.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Tandem Diabetes Care.

Tandem Diabetes Care is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Tandem Diabetes Care.

Tandem Diabetes Care will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Tandem Diabetes Care Inc (NASDAQ:TNDM) released its earnings results on Thursday, July, 30th. The medical device company reported ($0.45) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.24) by $0.21. The medical device company earned $109.24 million during the quarter, compared to analysts' expectations of $86.51 million. Tandem Diabetes Care had a negative net margin of 10.29% and a negative return on equity of 12.88%.
View Tandem Diabetes Care's earnings history.

Tandem Diabetes Care's stock reverse split on Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split.

14 brokerages have issued 12 month price targets for Tandem Diabetes Care's stock. Their forecasts range from $75.00 to $140.00. On average, they expect Tandem Diabetes Care's stock price to reach $113.86 in the next twelve months. This suggests a possible upside of 4.5% from the stock's current price.
View analysts' price targets for Tandem Diabetes Care.

Some companies that are related to Tandem Diabetes Care include FRESENIUS SE &/S (FSNUY), Teleflex (TFX), Insulet (PODD), ABIOMED (ABMD), Novocure (NVCR), Penumbra (PEN), Irhythm Technologies (IRTC), Hill-Rom (HRC), Haemonetics (HAE), Nevro (NVRO), Globus Medical (GMED), ICU Medical (ICUI), Integra LifeSciences (IART), Inari Medical (NARI) and Inspire Medical Systems (INSP).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Square (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL).

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

Tandem Diabetes Care's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Columbus Circle Investors (0.94%), Chicago Capital LLC (0.72%), Scout Investments Inc. (0.17%), Copper Rock Capital Partners LLC (0.12%), Ziegler Capital Management LLC (0.09%) and State of New Jersey Common Pension Fund D (0.06%). Company insiders that own Tandem Diabetes Care stock include Brian B Hansen, Christopher J Twomey, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Howard E Greene Jr, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, Rebecca B Robertson, Richard P Valencia and Susan Morrison.
View institutional ownership trends for Tandem Diabetes Care.

TNDM stock was sold by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Copper Rock Capital Partners LLC, Hodges Capital Management Inc., Ziegler Capital Management LLC, BNP Paribas Arbitrage SA, Dupont Capital Management Corp, Comerica Bank, and Candriam Luxembourg S.C.A.. Company insiders that have sold Tandem Diabetes Care company stock in the last year include Brian B Hansen, Christopher J Twomey, David B Berger, Dick Allen, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, Rebecca B Robertson, and Susan Morrison.
View insider buying and selling activity for Tandem Diabetes Care.

TNDM stock was purchased by a variety of institutional investors in the last quarter, including Highland Capital Management LLC, Avantax Advisory Services Inc., Assenagon Asset Management S.A., Polianta Ltd, WINTON GROUP Ltd, Envestnet Asset Management Inc., Wedbush Securities Inc., and Manchester Capital Management LLC.
View insider buying and selling activity for Tandem Diabetes Care.

Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TNDM stock can currently be purchased for approximately $109.00.

Tandem Diabetes Care has a market capitalization of $6.64 billion and generates $362.30 million in revenue each year. The medical device company earns $-24,750,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis. Tandem Diabetes Care employs 1,043 workers across the globe.

The official website for Tandem Diabetes Care is www.tandemdiabetes.com.

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company can be reached via phone at 858-366-6900 or via email at [email protected]